Preclinical sustained analgesia and translational potential of AAV-encoded CaV3.2 peptide aptamers for peripherally targeted pain therapy
Molecular Therapy: Nucleic Acids
· Elsevier
Аннотация
Publication date: 8 December 2026 Source: Molecular Therapy Nucleic Acids, Volume 37, Issue 4 Author(s): Seung Min Shin, Brandon Itson-Zoske, Xiaolin Wu, Seung-Keun Hong, Yongsong Cai, Fan Fan, Hongwei Yu
Читать у издателя →
Цитировать
Получайте новые статьи по теме «Поиск и разработка лекарств»
Подписка, поиск по ключевым словам и избранное — в Telegram-боте Articlium.
Открыть в Telegram
Цитирование
✕
ГОСТ
APA
MLA
BibTeX
Preclinical sustained analgesia and translational potential of AAV-encoded CaV3.2 peptide aptamers for peripherally targeted pain therapy. // Molecular Therapy: Nucleic Acids. – URL: https://www.sciencedirect.com/science/article/pii/S2162253126003136?dgcid=rss_sd_all
Preclinical sustained analgesia and translational potential of AAV-encoded CaV3.2 peptide aptamers for peripherally targeted pain therapy. Molecular Therapy: Nucleic Acids. https://www.sciencedirect.com/science/article/pii/S2162253126003136?dgcid=rss_sd_all
“Preclinical sustained analgesia and translational potential of AAV-encoded CaV3.2 peptide aptamers for peripherally targeted pain therapy.” Molecular Therapy: Nucleic Acids.
@article{article59109,
title = {Preclinical sustained analgesia and translational potential of AAV-encoded CaV3.2 peptide aptamers for peripherally targeted pain therapy},
journal = {Molecular Therapy: Nucleic Acids},
url = {https://www.sciencedirect.com/science/article/pii/S2162253126003136?dgcid=rss_sd_all}
}